STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1082 by analyst upside · 2026-06-27
BSX
Boston Scientific Corporation
Healthcare · Market Cap $66B · P/E 18.5x
ANALYST PRICE TARGET
+69.6%
implied upside to consensus target
Current Price $44.23
Consensus Target $75.0
Bull Target $106.0
Bear Target $55.0
Analysts Covering 29
ANALYST CONSENSUS - BUY
Strong Buy
9
Buy
20
Hold
0
Sell
0
52-Week Low $43.89
52-Week High $109.5
YTD Return -53.3%
FUNDAMENTALS
Market Cap $66B
P/E Ratio (TTM) 18.5x
Forward P/E 11.9x
EPS (TTM) $2.39
PEG Ratio 0.54
Dividend Yield N/A
Revenue (TTM) $20.6B
Profit Margin 17.3%
52-WEEK RANGE
52-Week Low $43.89
52-Week High $109.5
Current Price $44.23
Bear Target $55.0
Bull Target $106.0
● Now $44.23 ● Target $75.0
TRADING DATA
Avg Volume 20.2M
YTD Return -53.3%
Analyst Count 29
Consensus Buy
Upside to Target +69.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Boston Scientific Corporation (BSX) is currently trading at $44.23 with a Wall Street consensus price target of $75.0, implying potential upside of 69.6% over the next 12 months. 29 analysts currently cover BSX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $106.0, while the most cautious has a target of $55.0.

BSX operates in the Healthcare sector with a market capitalisation of $66B. The stock is down 53.3% year-to-date and is currently trading near the lower end of its 52-week range of $43.89 – $109.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BSX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-06-16 38% win rate (8 calls)
Truist Securities — Reiterated
Buy → Buy 2026-06-04 Building track record
BTIG — Reiterated
Buy → Buy 2026-06-03 38% win rate (8 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-06-01 Building track record
Wolfe Research ↓ Downgrade
Outperform → Peer Perform 2026-05-29 Building track record
Citigroup — Reiterated
Buy → Buy 2026-05-28 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-05-28 29% win rate (7 calls)
Barclays — Reiterated
Overweight → Overweight 2026-05-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
60
out of 100
Coverage depth
26/30
Consensus clarity
7/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →